Fortrea Holdings (FTRE) Revenue (2022 - 2026)
Fortrea Holdings (FTRE) reported Revenue of $636.5 million for Q1 2026, down 2.27% on a YoY basis from $651.3 million in Q1 2025, and down 3.63% quarter-over-quarter from $660.5 million in Q4 2025.
Fortrea Holdings (FTRE) Revenue (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported Revenue for 5 years, with the latest figure at $636.5 million in Q1 2026.
- For the quarter ending Q1 2026, Revenue fell 2.27% year-over-year to $636.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 billion (up 0.86% YoY), and the FY2025 full-year result was $2.7 billion, up 1.0% from the prior year.
- Revenue for Q1 2026 stood at $636.5 million, down from $660.5 million in the prior quarter.
- The five-year high for Revenue was $793.1 million in Q2 2022, with the low at $502.6 million in Q4 2022.
- Historically, Revenue has averaged $684.8 million across 5 years, with a median of $695.4 million in 2023.
- Annual changes were most pronounced in 2023 — Revenue surged 41.21% — and 2024, when it dropped 8.65%.
- Fortrea Holdings' Revenue stood at $502.6 million in 2022, then surged by 41.21% to $709.7 million in 2023, then decreased by 1.79% to $697.0 million in 2024, then dropped by 5.24% to $660.5 million in 2025, then retreated by 3.63% to $636.5 million in 2026.
- The last three Revenue figures came in at $636.5 million (Q1 2026), $660.5 million (Q4 2025), and $701.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 5.21 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 306.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.99 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | 636.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 636.50 Mn |
| Dec 31, 2025 | 660.50 Mn |
| Sep 30, 2025 | 701.30 Mn |
| Jun 30, 2025 | 710.30 Mn |
| Mar 31, 2025 | 651.30 Mn |
| Dec 31, 2024 | 697.00 Mn |
| Sep 30, 2024 | 674.90 Mn |
| Jun 30, 2024 | 662.40 Mn |
| Mar 31, 2024 | 662.10 Mn |
| Dec 31, 2023 | 709.70 Mn |
| Sep 30, 2023 | 713.80 Mn |
| Jun 30, 2023 | 725.10 Mn |
| Mar 31, 2023 | 693.90 Mn |
| Dec 31, 2022 | 502.60 Mn |
| Sep 30, 2022 | 762.30 Mn |
| Jun 30, 2022 | 793.10 Mn |